Geron Announces Publication Demonstrating Activity of Imetelstat

Geron Corporation GERN today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat, currently in Phase 2 clinical trials, selectively targets cancer stem cells in pediatric tumors of neural origin.